Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
491.73M | 398.20M | 214.20M | 140.83M | 119.07M | Gross Profit |
422.89M | 313.67M | 179.81M | 118.95M | 102.03M | EBIT |
195.12M | 86.81M | 101.84M | 52.38M | 41.30M | EBITDA |
195.12M | 119.69M | 101.84M | 52.38M | 41.30M | Net Income Common Stockholders |
163.89M | 71.41M | 83.08M | 39.48M | 74.98M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
517.55M | 137.64M | 298.39M | 191.27M | 140.28M | Total Assets |
851.41M | 470.11M | 375.63M | 237.79M | 192.35M | Total Debt |
2.79M | 3.56M | 3.89M | 3.89M | 28.77K | Net Debt |
-514.77M | -134.08M | -294.50M | -167.55M | -130.21M | Total Liabilities |
123.78M | 82.23M | 75.21M | 30.96M | 22.76M | Stockholders Equity |
727.63M | 387.88M | 300.42M | 206.83M | 169.60M |
Cash Flow | Free Cash Flow | |||
143.37M | -54.92M | 116.02M | 59.35M | 45.02M | Operating Cash Flow |
143.60M | 143.60M | 116.05M | 60.37M | 45.03M | Investing Cash Flow |
-293.50M | -293.50M | 9.21M | -11.02M | -5.01M | Financing Cash Flow |
-10.86M | -10.86M | 1.69M | -8.14M | 701.93K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $2.93B | 17.63 | 29.38% | ― | 23.49% | 104.96% | |
78 Outperform | $67.45B | 16.09 | 15.95% | 0.14% | 8.27% | 10.35% | |
78 Outperform | $12.87B | 30.68 | 8.05% | ― | 17.35% | 151.40% | |
75 Outperform | $166.45B | 40.98 | 67.55% | 2.95% | 18.64% | -39.39% | |
64 Neutral | $124.29B | ― | -3.15% | ― | 11.64% | -114.72% | |
54 Neutral | $3.30B | ― | -214.50% | ― | 29.01% | 23.93% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% |
On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors of Catalyst Pharmaceuticals, announced he would not seek reelection at the 2025 annual stockholders’ meeting, concluding his long-standing service on the Board since 2004. His decision was not due to any disagreement with the company. The company plans to hire a recruitment firm to find a new director, marking a significant transition in its leadership structure.
Catalyst Pharmaceuticals has released a corporate presentation that outlines their strategic focus on rare diseases, particularly through their flagship product FIRDAPSE for Lambert Eaton myasthenic syndrome (LEMS) and the novel corticosteroid AGAMREE for Duchenne Muscular Dystrophy (DMD). The presentation highlights the company’s growth strategy, market opportunities, and patient-centric initiatives, showcasing their strong financial performance and future potential in expanding patient access and market penetration in these niche therapeutic areas.